125 related articles for article (PubMed ID: 12902814)
1. Changes in metabolic profile among antiretroviral-naive patients initiating protease inhibitor versus non-protease inhibitor containing HAART regimens.
Visnegarwala F; Darcourt J; Sajja P; Menon V; Ong O; Maldonado M; White AC
J Acquir Immune Defic Syndr; 2003 Aug; 33(5):653-5. PubMed ID: 12902814
[No Abstract] [Full Text] [Related]
2. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
[TBL] [Abstract][Full Text] [Related]
3. Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir.
Miró O; Garrabou G; López S; Deig E; Vidal I; Infante AB; Cardellach F; Casademont J; Pedrol E
Antivir Ther; 2006; 11(5):625-30. PubMed ID: 16964831
[TBL] [Abstract][Full Text] [Related]
4. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy.
Shlay JC; Bartsch G; Peng G; Wang J; Grunfeld C; Gibert CL; Visnegarwala F; Raghavan SS; Xiang Y; Farrough M; Perry HE; Kotler D; El-Sadr WM
J Acquir Immune Defic Syndr; 2007 Apr; 44(5):506-17. PubMed ID: 17325603
[TBL] [Abstract][Full Text] [Related]
5. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.
d'Arminio Monforte A; Lepri AC; Rezza G; Pezzotti P; Antinori A; Phillips AN; Angarano G; Colangeli V; De Luca A; Ippolito G; Caggese L; Soscia F; Filice G; Gritti F; Narciso P; Tirelli U; Moroni M
AIDS; 2000 Mar; 14(5):499-507. PubMed ID: 10780712
[TBL] [Abstract][Full Text] [Related]
6. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
Wood E; Hogg RS; Heath KV; de la Rosa R; Lee N; Yip B; O'Shaughnessy MV; Montaner JS
AIDS; 2003 Dec; 17(18):2629-34. PubMed ID: 14685057
[TBL] [Abstract][Full Text] [Related]
7. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Jaspan HB; Berrisford AE; Boulle AM
Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
[TBL] [Abstract][Full Text] [Related]
8. Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.
Crane HM; Van Rompaey SE; Kitahata MM
AIDS Patient Care STDS; 2007 Dec; 21(12):920-9. PubMed ID: 18154489
[TBL] [Abstract][Full Text] [Related]
9. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
Cuzin L; Allavena C; Morlat P; Dellamonica P
AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
[TBL] [Abstract][Full Text] [Related]
10. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
[TBL] [Abstract][Full Text] [Related]
11. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses.
Chou R; Fu R; Huffman LH; Korthuis PT
Lancet; 2006 Oct; 368(9546):1503-15. PubMed ID: 17071284
[TBL] [Abstract][Full Text] [Related]
12. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy.
Hatano H; Miller KD; Yoder CP; Yanovski JA; Sebring NG; Jones EC; Davey RT
AIDS; 2000 Sep; 14(13):1935-42. PubMed ID: 10997397
[TBL] [Abstract][Full Text] [Related]
13. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
[TBL] [Abstract][Full Text] [Related]
14. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
15. The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection.
Klein MB; Willemot P; Murphy T; Lalonde RG
AIDS; 2004 Sep; 18(14):1895-904. PubMed ID: 15353975
[TBL] [Abstract][Full Text] [Related]
16. Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).
Pulido F; Arribas JR; Miró JM; Costa MA; González J; Rubio R; Peña JM; Torralba M; Lonca M; Lorenzo A; Cepeda C; Vázquez JJ; Gatell JM;
J Acquir Immune Defic Syndr; 2004 Apr; 35(4):343-50. PubMed ID: 15097150
[TBL] [Abstract][Full Text] [Related]
17. Effects of first antiretroviral regimen on lipid levels in HIV (+) individuals.
Papadopoulos A; Pantazis N; Panagopoulos P; Kourkounti S; Xylomenos G; Chini M; Petrikkos G; Sambatakou H; Ioannidou P; Kordosis T; Panos G; Touloumi G
J Chemother; 2012 Feb; 24(1):38-47. PubMed ID: 22546723
[TBL] [Abstract][Full Text] [Related]
18. CD4 cell count response to nonnucleoside reverse transcriptase inhibitor- or protease inhibitor-based highly active antiretroviral therapy in an observational cohort study.
Wood E; Hogg RS; Yip B; O'Shaughnessy MV; Montaner JS
J Acquir Immune Defic Syndr; 2003 Nov; 34(3):347-8. PubMed ID: 14600584
[No Abstract] [Full Text] [Related]
19. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors.
Melvin AJ; Lennon S; Mohan KM; Purnell JQ
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1117-23. PubMed ID: 11522181
[TBL] [Abstract][Full Text] [Related]
20. Relapse of Kaposi's sarcoma in HIV-infected patients switching from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimen.
Bani-Sadr F; Fournier S; Molina JM
AIDS; 2003 Jul; 17(10):1580-1. PubMed ID: 12824806
[No Abstract] [Full Text] [Related]
[Next] [New Search]
